Furthermore, the effect of ligand and solvent choice is often subtle and unpredictable. This perspective describes how two statistical techniques, design of experiments (DoE) and principal component analysis (PCA), can be combined to guide the decision-making process. The general approach to using these techniques is described, and illustrated with a brief worked example on challenging ‘borrowing hydrogen’ chemistry. The unique combination of DoE and PCA is a useful decision-making tool to support the selection of ligands and solvents for challenging catalytic reactions. (c) 2014 Society of Chemical Industry”
“The find more effects of electronic wave function hybridization are studied in In (Ga)As/GaAs dot

chain samples by means of continuous wave and time resolved photoluminescence BI6727 (PL). A set of wetting layer (WL) states strongly coupled with the quantum dot (QD) heavy hole states is revealed in the PL. The hybridization of states is favored by the presence of a specific one-dimensional postwetting layer that strings together the QDs in each chain. It is demonstrated that the strength of hybridization is significantly weakened for states deep in the WL gap. The hybridization of the WL states and the QD hole

states substantially affects the rates of carrier trapping by the QDs and the carrier distribution. Specific convex shape of the PL transients is related to the presence of long living localized states in the WL energy gap. (c) 2009 American Institute of Physics. [DOI: 10.1063/1.3151707]“
“Tissue engineered bone grafts have the potential to be used to treat large bone defects check details due to congenital abnormalities, cancer resections, or traumatic incidents. Recent studies have shown that perfusion bioreactors can be

used to generate grafts of clinically relevant sizes and shapes. Despite these scientific and technological successes, there is uncertainty regarding the translational utility of bioreactor-based approaches due to the perceived high costs associated with these procedures. In fact, experiences over the past two decades have demonstrated that the widespread application of cell-based therapies is heavily dependent on the commercial viability. In this article, we directly address the question of whether bioreactors used to create bone grafts have the potential to be implemented in clinical approaches to bone repair and regeneration. We provide a brief review of tissue engineering approaches to bone repair, clinical trials that have employed cell-based methods, and advances in bioreactor technologies over the past two decades. These analyses are combined to provide a perspective on what is missing from the scientific literature that would enable an objective baseline for weighing the benefit of extended in vitro cultivation of cells into functional bone grafts against the cost of additional cultivation.